Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
10635 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 5743
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (PFA) System… NCT07925359 · NAVigate-ULTRA — The Evaluation of User Experience With FARAVIEW™ Technology of… | Maladie coronarienne | À vérifier | Non applicable | NOT_YET_RECRUITING | The objective of this study is to obtain experience with new and modified… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| SESAME Procedure NCT07806149 · NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective… | Maladie coronarienne | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | This is an early study of a catheter-based minimally invasive procedure ca… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| Topical cyanoacrylate tissue adhesive NCT07926191 · Tissue Adhesive Versus Figure-of-Eight Suture for Femoral Venous Closure After E… | Maladie coronarienne | Thérapie génique | À vérifier | NOT_YET_RECRUITING | In July 2026 the electrophysiology laboratory of a Czech tertiary cardiolo… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| Truvaga Plus NCT07926945 · U54: nVNS RCT — Effects of nVNS on Stress Reactivity in IBS | Maladie coronarienne | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interact… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:06 | Détail |
| Capstan Compass Robotic System for Transcatheter Mitral Valve Replace… NCT07917208 · Early Feasibility Study of the Capstan Medical TMVR System | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | This early feasibility study is evaluating the safety and performance of t… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Discontinuation of aspirin (ATC-code B01AC06 and N02BA01) NCT07854795 · RELEASE-Norway — Reconsidering Long-Term Apirin in the Elderly in Secondary Prev… | Maladie coronarienne | À vérifier | Phase 4 | NOT_YET_RECRUITING | Lifelong aspirin has been a cornerstone of secondary prevention after coro… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Extracorporeal Shock Wave Therapy NCT07068399 · CSWT — Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronar… | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | This randomized single-blind controlled trial aims to compare the effectiv… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Modified ultrafiltration NCT00246779 · A Study of the Effect of Blinding in a Trial of Blood Filtration During Heart Su… | Maladie coronarienne | À vérifier | Non applicable | COMPLETED | Cardiac surgery is a major consumer of blood products worldwide. The natur… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Naproxen NCT07549490 · Human Experimental Models of Pain (HEMP) | Maladie coronarienne | Immunomodulation · Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | This pilot study will test an innovative way to establish how pain medicin… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Prescription of Aspirin NCT07524335 · ASCAD-P — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Con… | Maladie coronarienne | À vérifier | Phase 3 | RECRUITING | In patients with subclinical coronary artery disease, the ASCAD-P study ai… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Pulmonary Vein Isolation NCT06402617 · RETRO-AF — Ablation of Focal Activation in Atrial Fibrillation | Maladie coronarienne | Ralentissement de la progression | Non applicable | RECRUITING | Atrial Fibrillation (AF) and Heart Failure (HF) are colliding global cardi… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Serratus Posterior Superior Intercostal Plane Block With Bupivacaine NCT07588230 · Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardia… | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | This randomized, double-blind, placebo-controlled study aims to evaluate t… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| TAVI NCT07926022 · TAVI and PCI in Comparison to SAVR and CABG in Low and Intermediate Risk Patient… | Maladie coronarienne | À vérifier | À vérifier | RECRUITING | \# WHAT IS THIS STUDY ABOUT? This study compares two different treatment a… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| This study involved an auxillary CE-marked medical device (implantabl… NCT07545512 · ODISSEY — ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Car… | Maladie coronarienne | Traitement symptomatique | Non applicable | RECRUITING | Although advances in treatment and patient management have considerably im… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:05 | Détail |
| Evolocumab NCT05284747 · EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Maladie coronarienne | À vérifier | Phase 4 | ACTIVE_NOT_RECRUITING | The primary objective of this study is to evaluate the effectiveness of ea… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| Microaxial flow pump (left ventricular assist device) NCT07762560 · DOUBLE-SHOCK — Routine Microaxial Heart Pump Support and Protocolized Pulmonary… | Maladie coronarienne | Thérapie génique | Non applicable | RECRUITING | The goal of this clinical trial is to learn which treatment strategies imp… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| No aspirin (Prasugurel monotherapy) NCT05709626 · PREMIUM — PRasugrEl Monotherapy Following prImary percUtaneous Coronary Interven… | Maladie coronarienne | À vérifier | Phase 4 | COMPLETED | The aim of this study is to evaluate the safety of prasugrel monotherapy w… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| Percutaneous Mechanical Circulatory Support NCT06445608 · PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | Maladie coronarienne | À vérifier | Non applicable | RECRUITING | This purpose of this trial is to demonstrate 30 day safety and effectivene… À vérifier | ClinicalTrials.gov 2026-11-09 21:03:04 | Détail |
| 26G Needle NCT07926113 · MASS-NEEDLE — Comparison of 26G and 30G Needles for Masseter Trigger Point Injec… | Myopathies | Traitement symptomatique | Non applicable | NOT_YET_RECRUITING | This randomized split-face study aims to compare the effects of 26G and 30… À vérifier | ClinicalTrials.gov 2026-11-09 21:02:59 | Détail |
| ABSK021 NCT04192344 · A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in… | Myopathies | À vérifier | Phase 1 | RECRUITING | This is an open-label phase 1 study to determine the safety and tolebility… À vérifier | ClinicalTrials.gov 2026-11-09 21:02:59 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4871
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Efficacy and safety of ocrelizumab in primary progressive multiple sc… Risk Perception in Multiple Sclerosis · PMID 42208561 | Sclérose en plaques | Ralentissement de la progression | Publication | PubMed | Voir la publication source The ORATORIO trial showed that ocrelizumab reduced the risk of disability progression versus placebo in patients with p… | Lancet (London, England) 2026-08-08 00:55:32 | Source |
| Pressure Ulcer Prevention at Home for People with Long-term Neurologi… Risk Perception in Multiple Sclerosis · PMID 42246207 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Many people with long-term neurological conditions (e.g. multiple sclerosis, spina bifida) live independently and manag… | Health and social care delivery research 2026-08-08 00:55:32 | Source |
| Hyodeoxycholic acid suppresses hepatic steatosis in a PPARα-dependent… GLP-1 · PMID 42566309 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Hepatosteatosis is a common metabolic disorder. Bile acids influence hepatosteatosis, immune function, and incretin sec… | Cell reports 2026-08-08 00:55:30 | Source |
| Natalizumab is associated with improved relapse outcomes and lower he… Ocrelizumab (US) · PMID 42323726 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Natalizumab (NTZ) and ocrelizumab (OCR) are well-established therapies and commonly considered first-line for newly dia… | Journal of medical economics 2026-08-08 00:55:30 | Source |
| Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2… GLP-1 · PMID 42566276 | Maladie rénale chronique | À vérifier | Publication | PubMed | Voir la publication source Chronic kidney disease (CKD) is associated with a higher risk of sepsis and poorer clinical outcomes compared to the ge… | Nephrology, dialysis, transplantation : official publi… 2026-08-08 00:55:30 | Source |
| Two Years of Ocrelizumab Treatment in Black and Hispanic People with… Ocrelizumab (US) · PMID 42530333 | Sclérose en plaques | Ralentissement de la progression | Publication | PubMed | Voir la publication source To evaluate the effectiveness and safety of ocrelizumab in self-identified black and Hispanic people with relapsing mul… | Annals of neurology 2026-08-08 00:55:30 | Source |
| Discontinuation of disease-modifying therapies in patients with multi… injectable MS DMT · PMID 42385519 | Sclérose en plaques | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source The long-term benefit-risk balance of disease-modifying therapies (DMTs) in multiple sclerosis (MS) becomes increasingl… | Multiple sclerosis and related disorders 2026-08-08 00:55:28 | Source |
| Between-hospital variation in discontinuation of treatment with dimet… dimethyl fumarate · PMID 42561744 | Sclérose en plaques | Ralentissement de la progression | Publication | PubMed | Voir la publication source In multiple sclerosis (MS), switching disease modifying treatment is associated with higher relapse rate, healthcare ex… | Multiple sclerosis and related disorders 2026-08-08 00:55:27 | Source |
| Pharmacological Modulation of Nrf2 Signaling Regulates Oxidative Stre… dimethyl fumarate · PMID 42552875 | Sclérose en plaques | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source To investigate whether pharmacological modulation of Nrf2 signaling influences oxidative stress, inflammatory responses… | Journal of periodontal research 2026-08-08 00:55:27 | Source |
| Association of Vitamin C Supplementation and Genetic Susceptibility w… Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility · PMID 425… | Sclérose en plaques | Neuroprotection | Publication | PubMed | Voir la publication source Multiple sclerosis (MS) is a chronic immune-mediated neurological disorder for which few modifiable risk factors are es… | Nutrients 2026-08-08 00:55:26 | Source |
| A network-based brain stimulation paradigm for alcohol use disorder w… Transcranial Magnetic Stimulation (TMS) · PMID 42564066 | Sclérose en plaques | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Alcohol use disorder (AUD) is frequently complicated by co-occurring major depressive disorder (MDD), a comorbidity ass… | Frontiers in neurology 2026-08-08 00:55:25 | Source |
| Spatiotemporal Brain Dynamics of Transitive and Intransitive Action O… Transcranial Magnetic Stimulation (TMS) · PMID 42565289 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Observing another person's action recruits the action observation network (AON). Evidence suggests that distinct AON pa… | Human brain mapping 2026-08-08 00:55:25 | Source |
| Urinary tract infections, urosepsis, and multiple sclerosis disease m… Interferon beta 1a · PMID 42435648 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source Infection-related complications, including urinary tract infections (UTIs) and urosepsis, account for a significant pro… | Multiple sclerosis and related disorders 2026-08-08 00:55:24 | Source |
| Catalysing tuberculosis elimination in Indonesia: Health economic and… rifampicin · PMID 42566457 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Indonesia diagnoses roughly 24,000 multidrug-resistant tuberculosis (MDR-TB) cases each year, 8% of the world's total.… | PloS one 2026-08-08 00:55:21 | Source |
| Rare primary bone tuberculosis associated with ruxolitinib therapy: A… rifampicin · PMID 42566613 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source Ruxolitinib, a Janus kinase (JAK) inhibitor, may increase the risk of tuberculosis infection by suppressing cellular im… | Medicine 2026-08-08 00:55:21 | Source |
| PGC-1α mediates ER stress-driven apoptotic signaling during gemfibroz… gemfibrozil · PMID 42521139 | Sclérose en plaques | Remyélinisation indirecte / réparation · Neuroprotection · Ralentissement de la… | Publication | PubMed | Voir la publication source Glioblastoma (GBM) is a highly aggressive and therapy-resistant brain tumor. In our earlier study, we demonstrated that… | European journal of pharmacology 2026-08-08 00:55:20 | Source |
| Silver(I)-Catalyzed A3-Coupling for the Regioselective Synthesis of 2… gemfibrozil · PMID 42565617 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source We report a silver(I)-catalyzed three-component A3-coupling strategy for the synthesis of 2-chloro-(phenylvinyl)imidazo… | The Journal of organic chemistry 2026-08-08 00:55:20 | Source |
| Chronic exposure to mining-contaminated borehole water impairs the en… Alpha Lipoic Acid · PMID 42541147 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Mining activities, industrial discharges, and poor waste management in many developing countries, including Nigeria, ha… | Frontiers in toxicology 2026-08-08 00:55:19 | Source |
| Thioctic acid-based adsorbent for heavy metal removal (Cd, Pb, and Cu… Alpha Lipoic Acid · PMID 42565172 | Sclérose en plaques | Remyélinisation indirecte / réparation | Publication | PubMed | Voir la publication source Low-molecular-weight organosulfur compounds possess well-defined metal-binding functionalities; however, their direct a… | RSC advances 2026-08-08 00:55:19 | Source |
| Analysis of the Main Directions in the Development of Mono and Combin… Everolimus Oral Product · PMID 40103456 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Hormone signaling plays a significant role in cancerogenesis. This review presents a comprehensive analysis of FDA-appr… | Current medicinal chemistry 2026-08-08 00:55:17 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||